Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)
Cardiac bypass surgery is an important treatment for patients with severely blocked arteries (tubes that delivery oxygen and nutrients to the heart). Hundreds of thousands of these operations are done each year to help relieve patients' chest pain and to prevent future heart attacks. The surgery is done by "bypassing" blood flow around badly clogged arteries by sewing on healthy vessels from another part of the body (usually from the leg or the chest). Aspirin (a blood thinner) is given to patients once a day after their surgery because it stops "sticky" cells in the blood (platelets) from blocking these new vessels (which may lead to a future heart attack).
Research has shown that aspirin does not work as well in people after they have bypass surgery as the investigators might expect (for reasons that are not fully understood). One reason aspirin may not work as well after surgery is because the body makes many more platelets after surgery than it would under normal circumstances. All of these new platelets overwhelm the aspirin and continue to be "sticky" and ready to block off arteries. The investigators believe that giving multiple daily doses of aspirin following bypass surgery is more effective than giving aspirin once daily at blocking platelet activity.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Background:
Cardiovascular disease caused by athero-thrombosis is the number one cause of long-term morbidity and death worldwide. Many patients with advanced coronary disease benefit from Coronary Artery Bypass Graft (CABG) by improving symptoms and increasing their longevity.
However, the benefits of CABG surgery are attenuated by early graft failure. The administration of aspirin in the post-operative period has been shown in randomized controlled trials (RCT) to reduce the risk of graft occlusion, although rates remain unacceptably high. Patients undergoing CABG surgery transiently develop aspirin resistance, which likely contributes to vein graft failure.
The investigators believe the aspirin resistance is a consequence of rapid platelet turnover in the early postoperative period, resulting in a large number of platelets unexposed to aspirin (due to its short half life). The investigators hypothesize that by increasing the frequency of aspirin dosing, the investigators can reverse the aspirin resistance encountered post CABG surgery. The investigators are proposing a RCT comparing two different doses of aspirin (81mg and 325mg daily) to 81mg qid to determine whether multiple daily dosing can overcome aspirin resistance.
(1)Given that platelet production is increased many-fold after CABG surgery (and the short half-life of aspirin), the investigators hypothesize that increasing the frequency of aspirin dosing will lead to the acetylation of a greater number of platelets over the course of the day leading to an improved antiplatelet effect (as measured by serum thromboxane and platelet aggregation assays); (2) The investigators will examine three platelet-related single nucleotide polymorphisms (SNP) that have been implicated in aspirin hyporesponsiveness.
The investigators are proposing a single centre, randomized, open-label, RCT in 60 patients undergoing elective or urgent CABG surgery, to receive ASA 81mg daily, 325mg daily or 81 mg qid starting day 1 post-operatively. All patients will receive 325mg 6hrs following the procedure (day of operation) as long as there is no contraindication for antiplatelet therapy (ie significant bleeding) - as per the investigators centre's standard clinical practice. Further details on aspirin administration and outcome measurements are reported below.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8L2X2
- Hamilton General Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult subjects who undergo elective or urgent CABG surgery who are on or off aspirin during the preoperative period
Exclusion Criteria:
- (a) initial platelet count <100,000 (b) significant liver disease (c) renal impairment (CrCl<30 ml/min/1.73 m2) (d) receiving (or planned) clopidogrel therapy (e) receiving NSAIDs or other drugs that might interfere with aspirin's platelet-inhibitory effect (f) need for therapeutic doses of parenteral or oral anticoagulants after surgery and (g) off-pump CABG (h) clinically important bleeding (chest tube drainage >200ml/hr for 6hrs)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Aspirin 81mg daily
Patients will receive 81mg daily during the postoperative period.
|
Aspirin 81 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 325 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 81mg po four times daily x 7days or end of hospitalization.
First dose administered on post op day 1.
|
|
Aktiv komparator: Aspirin 325mg dagligen
Patienterna kommer att få 325 mg dagligen under den postoperativa perioden, fram till dag 7 postop eller slutet av sjukhusvistelsen.
|
Aspirin 81 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 325 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 81mg po four times daily x 7days or end of hospitalization.
First dose administered on post op day 1.
|
|
Experimentell: Aspirin 81mg four times daily
Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
|
Aspirin 81 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 325 mg per dag x 7 dagar eller slutet av sjukhusvistelsen.
Första dosen administrerad efter operation dag 1.
Aspirin 81mg po four times daily x 7days or end of hospitalization.
First dose administered on post op day 1.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Serum Thromboxane: Define an inadequate aspirin response as a value >0.69 ng/ml, which is 2 SD above the mean of aspirin-treated patients
Tidsram: Postoperative Day 4
|
Postoperative Day 4
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Arachidonic Acid Induced Light Transmission Aggregometry (LTA): Aggregation kommer att uttryckas som den maximala procentuella förändringen i ljustransmittans från baslinjen, med blodplättsfattig plasma som referens.
Tidsram: Postoperativ dag 4
|
Postoperativ dag 4
|
|
Arachidonic Acid Induced Multiple Electrode Platelet Aggregometry (MEA):Aggregation was recorded for 6 minutes and will be reported as the area under the curve (aggregation units x min).
Tidsram: Postoperative Day 4
|
Postoperative Day 4
|
|
DNA genetic analyses for single nucleotide polymorphisms
Tidsram: A single preoperative blood sample was drawn (on average of 1 week prior to surgery)
|
A single preoperative blood sample was drawn (on average of 1 week prior to surgery)
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jeremy Paikin, MD, Cardiology Fellow
- Huvudutredare: John Eikelboom, MBBS, Hematologist, PHRI researcher
- Huvudutredare: Richard Whitlock, MD, Cardiac Surgeon, PHRI researcher
- Huvudutredare: Guillaume Pare, MD, Medical Biochemist, PHRI researcher
- Studiestol: Jack Hirsh, MD, Hematologist, Professor Emeritus, PHRI researcher
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Agenter från det perifera nervsystemet
- Enzyminhibitorer
- Analgetika
- Sensoriska systemagenter
- Antiinflammatoriska medel, icke-steroida
- Analgetika, icke-narkotiska
- Antiinflammatoriska medel
- Antireumatiska medel
- Fibrinolytiska medel
- Fibrinmodulerande medel
- Trombocytaggregationshämmare
- Cyklooxygenashämmare
- Antipyretika
- Aspirin
Andra studie-ID-nummer
- NIF-11271
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .